Approaches to Simultaneous Analysis of Frequency and Severity of Symptoms

Mechanistic models that synthesize pharmacological and (patho)physiological process information provide a rich basis for the characterization of drug action. However, the underlying clinical data are often simplified in a manner that does not allow models to fully elucidate the structure of the drug effect. In this article, we describe data‐simplification strategies that are in routine use to describe disease symptoms and compare them with a model developed for handling the true complexities of the data.

[1]  D. Mould,et al.  A population pharmacokinetic‐pharmacodynamic and logistic regression analysis of lotrafiban in patients , 2001, Clinical pharmacology and therapeutics.

[2]  T. Craig,et al.  Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis , 2000, The Journal of the American Osteopathic Association.

[3]  Adrian Dunne,et al.  Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .

[4]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[5]  E Niclas Jonsson,et al.  More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.

[6]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[7]  Laura Iavarone,et al.  Population Pharmacokinetic-Pharmacodynamic Model of Craving in an Enforced Smoking Cessation Population: Indirect Response and Probabilistic Modeling , 2001, Pharmaceutical Research.

[8]  Lewis B. Sheiner,et al.  A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  Lewis B Sheiner,et al.  Determination of maximum effect. , 2002, Clinical pharmacology and therapeutics.

[10]  Lewis B. Sheiner,et al.  The Need for Mixed-Effects Modeling with Population Dichotomous Data , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  J Wakefield,et al.  Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores , 2001, Statistics in medicine.

[12]  Evaluation of Mixture Modeling with Count Data Using NONMEM , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  J. Verweij,et al.  Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.

[14]  H. T. Dombrowski.  Effective strategies for the prevention of osteoporosis across the life span. , 2000, The Journal of the American Osteopathic Association.

[15]  W. Busse,et al.  Characteristics of patients with seasonal allergic rhinitis and concomitant asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  D. Rubin,et al.  Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval , 2003, Clinical pharmacology and therapeutics.